C4 Therapeutics Inc

CCCC

Company Profile

  • Business description

    C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

  • Contact

    490 Arsenal Way
    Suite 120
    WatertownMA02472
    USA

    T: +1 617 231-0700

    https://www.c4therapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    110

Stocks News & Analysis

stocks

Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief

We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
stocks

ASX share ticks all the popular thematic boxes

The shares are overvalued as investors are overly excited about defence and gold exposure.
stocks

Bluescope offer knocked back by board

Our view on the potential for additional offers.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,138.5011.400.12%
CAC 408,313.0045.76-0.55%
DAX 4025,349.1556.19-0.22%
Dow JONES (US)49,590.2086.130.17%
FTSE 10010,141.630.930.01%
HKSE26,848.47239.990.90%
NASDAQ23,733.9062.560.26%
Nikkei 22553,549.161,609.273.10%
NZX 50 Index13,656.0527.24-0.20%
S&P 5006,977.2710.990.16%
S&P/ASX 2008,808.5017.200.20%
SSE Composite Index4,138.7626.53-0.64%

Market Movers